P. Armand

M. Perales, P. Armand, C. Sauter, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

M. Perales, P. Armand, C. Sauter, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT

R. Kwong, E. Neufeld, P. Armand, 2013, Bone Marrow Transplantation.

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

M. Fleming, H. Steen, R. Kwong, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune and Cell Therapy in Non-Hodgkin Lymphoma

R. Houot, P. Armand, C. Jacobson, 2020, Cancer journal.

Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

L. Vercellino, R. Houot, L. Schwartz, 2019, The Journal of Nuclear Medicine.

The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).

L. Gordon, J. Winter, J. Fay, 2009 .

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Sonali M. Smith, M. Norkin, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunotherapy in aggressive B-cell lymphomas.

P. Armand, C. Jacobson, 2018, Best practice & research. Clinical haematology.

Guideline Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma : Guidelines from the American Society for Blood and Marrow Transplantation

J. Vose, M. Perales, A. Evens, 2015 .

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

J. Vose, M. Perales, A. Evens, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

D. Neuberg, Catherine J. Wu, G. Dranoff, 2013, The Journal of clinical investigation.

Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant

P. Armand, R. Merryman, 2017, Current Hematologic Malignancy Reports.

A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020, Blood.

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.

P. Zinzani, P. Armand, J. Kuruvilla, 2020, Blood advances.

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

M. Shipp, N. Johnson, J. Radford, 2020, Leukemia & lymphoma.

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

J. Leonard, J. Radford, Hao Tang, 2020, Blood.

Pembrolizumab in relapsed or refractory Richter syndrome

A. Stathis, P. Armand, J. Pagel, 2020, British journal of haematology.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087.

M. Shipp, N. Johnson, J. Radford, 2019, Blood.

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.

A. LaCasce, M. Shipp, J. Ritz, 2018, Blood.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

K. Savage, M. Shipp, A. Ligon, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

K. Savage, D. Neuberg, G. Pinkus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

M. Shipp, P. Zinzani, P. Armand, 2017, Blood.

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

R. Advani, L. Gordon, L. Schwartz, 2016, Blood.

lymphoma: myeloablative or reduced intensity? Conditioning regimens for allotransplants for diffuse large B-cell

Sonali M. Smith, P. Hari, P. Armand, 2012 .

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

P. D. Dal Cin, N. Lindeman, D. Mandelker, 2015, Experimental Hematology & Oncology.

Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States

S. Sen, P. Armand, M. Duh, 2021, Journal of medical economics.

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

P. Armand, S. Schuster, C. Andreadis, 2019, The oncologist.

Sonographic Features of Pectoralis Muscle Necrosis Secondary to Gemcitabine‐Induced Radiation Recall

D. D. Di Salvo, P. Armand, M. Nishino, 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.

Matthew J. Frigault, R. Advani, A. LaCasce, 2021, Blood advances.

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Matthew J. Frigault, J. Ritz, D. Maloney, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

A. LaCasce, A. Freedman, P. Armand, 2020, Blood advances.

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.

R. Advani, Sonali M. Smith, A. Troxel, 2020, The oncologist.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

P. Hari, S. Mineishi, P. Armand, 2017, Blood.

A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma

A. LaCasce, M. Faham, L. Weng, 2016, British journal of haematology.

Checkpoint blockade in lymphoma.

P. Armand, 2015, Hematology. American Society of Hematology. Education Program.

Hodgkin Lymphoma and PD-1 Blockade

P. Armand, S. Ansell, R. Merryman, 2020, Hodgkin Lymphoma.

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Emily M. Thrash, Emma S. Hathaway, Shuqiang Li, 2021, Blood.

Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease.

P. Armand, R. Soiffer, C. Cutler, 2021, Transplantation and cellular therapy.

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

A. Jakubowiak, R. Vij, N. Munshi, 2011, The Lancet. Oncology.

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

J. Ritz, S. Nikiforow, P. Armand, 2020, Blood advances.

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

J. Ritz, P. Armand, R. Soiffer, 2013, Bone Marrow Transplantation.

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

K. Savage, M. Shipp, A. Santoro, 2016 .

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.

P. Armand, R. Soiffer, S. Koo, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2007, Blood.

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

J. Vose, M. Aljurf, R. Gale, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.

P. Armand, R. Soiffer, S. Koo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis

J. Ritz, J. Brown, K. Stevenson, 2011, Bone Marrow Transplantation.

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

M. Norkin, W. Wood, M. Aljurf, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

L. Rassenti, T. Kipps, J. Ritz, 2016, Blood.

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

I. Flinn, B. Keyt, P. Armand, 2021, Blood.

Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.

R. Parkkola, P. Armand, M. Itälä-Remes, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.

J. Ritz, P. Armand, D. DeAngelo, 2006 .

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

P. Armand, D. Fisher, R. Soiffer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma

E. D. Jacobsen, P. Armand, D. Fisher, 2022, Bone Marrow Transplantation.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

A. LaCasce, P. Armand, D. Fisher, 2018, The oncologist.

Emergency general surgery procedures in hematopoietic stem cell transplant recipients.

Tarsicio Uribe-Leitz, D. Nehra, M. Castillo-Angeles, 2019, American journal of surgery.

Stem Cell Transplantation for Marrow Failure

P. Armand, J. Antin, 2008 .

Allogeneic stem cell transplantation for aplastic anemia.

P. Armand, J. Antin, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2017, Blood.

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

A. LaCasce, D. Neuberg, B. Ebert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

J. Ritz, K. Stevenson, P. Armand, 2009, Blood.

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease

S. Nikiforow, P. Armand, R. Soiffer, 2020, Bone Marrow Transplantation.

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

L. Zon, W. Goessling, C. Desponts, 2013, Blood.

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.

J. Ritz, P. Armand, K. Ballen, 2011, Blood.

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

J. Ritz, S. Nikiforow, J. Whangbo, 2016, Blood.

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011, Clinical Cancer Research.

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood advances.

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood.

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation

A. LaCasce, P. Armand, D. Fisher, 2021, Leukemia & lymphoma.

A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.

M. Dolled-Filhart, K. Emancipator, P. Zinzani, 2014 .

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Catherine J. Wu, F. Hodi, Michael S. Rooney, 2016, The New England journal of medicine.

Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.

P. Armand, R. Soiffer, C. Cutler, 2006 .

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

S. Tyekucheva, P. Armand, M. Davids, 2020, Leukemia.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

P. Armand, C. Jacobson, Jennifer R. Brown, 2020 .

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

A. Alencar, A. LaCasce, S. Tyekucheva, 2019, The Lancet. Haematology.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

D. Neuberg, P. Armand, M. Davids, 2019, Leukemia & lymphoma.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

L. Rassenti, T. Kipps, A. Freedman, 2019, Blood advances.

Prediction of veno-occlusive disease using biomarkers of endothelial injury.

P. Richardson, J. Ritz, P. Armand, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

S. Nikiforow, P. Armand, K. Ballen, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

P. Zinzani, P. Armand, J. Palcza, 2019, Blood.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.

A. Sultan, P. Armand, R. Soiffer, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

M. Horowitz, P. Armand, R. Soiffer, 2014, Blood.

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

J. Ritz, K. Stevenson, P. Armand, 2010, Blood.

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

E. D. Jacobsen, P. Armand, D. Fisher, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

M. Millenson, M. Shipp, G. Freeman, 2015, The New England journal of medicine.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

P. Armand, K. Ballen, R. Soiffer, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

A. LaCasce, D. Neuberg, L. Rassenti, 2013, Haematologica.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Interleukin-2 and regulatory T cells in graft-versus-host disease.

J. Ritz, Sashank Prasad, D. Bienfang, 2011, The New England journal of medicine.

Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma.

A. LaCasce, J. Ritz, P. Armand, 2021, Transplantation and cellular therapy.

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

D. Neuberg, M. Shipp, X. Liu, 2020, Nature Medicine.

Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma

S. Ansell, P. Armand, A. Khurana, 2020, Leukemia & lymphoma.

Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.

Andrew J. Dunford, G. Getz, C. Stewart, 2019, Blood advances.

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative.

M. Shipp, S. Rodig, P. Armand, 2019, Blood.

Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

D. Neuberg, M. Shipp, X. Liu, 2018, Blood.

Mass cytometry of Hodgkin lymphoma reveals a CD 4 + exhausted T-effector and T-regulatory cell rich microenvironment

Robert, Redd, D. Neuberg, 2018 .

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

S. Rodig, P. Armand, R. Merryman, 2017, Blood advances.

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Y. Natkunam, R. Advani, D. de Jong, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

J. Ritz, K. Stevenson, P. Armand, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

M. Shipp, A. Ligon, S. Ansell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

A. LaCasce, M. Shipp, S. Mukundan, 2017, Blood.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

M. Millenson, M. Shipp, G. Freeman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma.

Matthew J. Frigault, P. Armand, M. Martinez-Lage, 2019, Blood.

Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

A. LaCasce, T. Batchelor, A. Muzikansky, 2012, Biology of Blood and Marrow Transplantation.

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

A. LaCasce, D. Neuberg, A. Freedman, 2013, Haematologica.

Immune checkpoint blockade in hematologic malignancies.

P. Armand, 2015, Blood.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A disease risk index for patients undergoing allogeneic stem cell transplantation.

H. Deeg, J. Ritz, M. Sorror, 2012, Blood.

Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.

A. LaCasce, D. Neuberg, M. Shipp, 2020, Blood.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, J. Whangbo, 2019, Blood advances.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

G. Salles, D. Neuberg, M. Shipp, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

J. Ritz, M. Tanimoto, P. Armand, 2017, Blood.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

R. Houot, J. Ritz, M. Perales, 2017, Blood.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

J. Ritz, S. Nikiforow, P. Armand, 2016, Haematologica.

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

J. Ritz, P. Armand, R. Soiffer, 2013, Blood.

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm

P. Armand, Jennifer L. Crombie, J. Crombie, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

I. Lossos, P. Armand, L. Alland, 2020, Blood.

High‐dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non‐Hodgkin Lymphoma With Synchronous Central Nervous System Involvement

T. Batchelor, P. Armand, Yi-Bin Chen, 2017, Clinical lymphoma, myeloma & leukemia.

High‐dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission

T. Batchelor, P. Armand, Yi-Bin Chen, 2017, Cancer.

Pulp Obliteration in a Patient with Sclerodermatous Chronic Graft-versus-Host Disease.

P. Armand, N. Treister, C. Gomes, 2016, Journal of endodontics.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, J. Whangbo, 2016, Blood.

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

J. Ritz, P. Armand, R. Soiffer, 2013, Science Translational Medicine.

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation

J. Ritz, S. Nikiforow, C. J. Luckey, 2016, Haematologica.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

D. Neuberg, B. Ebert, P. Stojanov, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

Emily B Hanhauser, M. Altfeld, D. Kuritzkes, 2014, Annals of Internal Medicine.

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Alan M. Miller, P. D. Dal Cin, J. Sierra, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

W. Pierceall, G. Shapiro, P. LoRusso, 2020, British Journal of Cancer.

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

P. Armand, K. Ballen, R. Soiffer, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.

J. Ritz, S. Nikiforow, E. Shpall, 2017, Cytotherapy.

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

J. Ritz, K. Stevenson, P. Armand, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

Hongye Liu, Masahiro Hirakawa, Kazuyuki Murase, 2016, JCI insight.

Donor and recipient sex in allogeneic stem cell transplantation: what really matters

Mei-Jie Zhang, Wael Saber, M. Perales, 2016, Haematologica.

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.

J. Ritz, P. Armand, K. Ballen, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation

J. Ritz, S. Nikiforow, P. Armand, 2019, Bone Marrow Transplantation.

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Catherine J. Wu, P. Armand, R. Soiffer, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

D. Leaf, J. Ritz, P. Armand, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-speciﬁc anti-HLA antibodies predict outcome in double umbilical cord blood transplantation

J. Ritz, P. Armand, K. Ballen, 2011 .

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation

S. Nikiforow, P. Armand, R. Soiffer, 2017, Haematologica.

phase 2 trial after allogeneic peripheral blood stem cell transplantation: results of a Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD

J. Ritz, P. Armand, R. Soiffer, 2014 .

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

J. Ritz, P. Armand, C. Jacobson, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome

J. Ritz, P. Armand, R. Soiffer, 2014, American journal of hematology.

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

J. Ritz, P. Armand, R. Soiffer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

J. Ritz, P. Armand, R. Soiffer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.

J. Ritz, S. Nikiforow, P. Armand, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome

J. Ritz, P. Armand, R. Soiffer, 2014 .

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.

J. Ritz, S. Nikiforow, P. Armand, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.

A. LaCasce, D. Kuritzkes, T. Henrich, 2013, The Journal of infectious diseases.

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

M. Shipp, P. Zinzani, G. Martinelli, 2014 .

The Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Raymond Y Huang, H. Kim, P. Armand, 2021, Cancers.

The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders

P. Armand, Jennifer L. Crombie, J. Crombie, 2019, Current Hematologic Malignancy Reports.

Minimal residual disease in non‐Hodgkin lymphoma – current applications and future directions

P. Armand, Matthew L Chase, 2018, British journal of haematology.

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome

J. Gribben, Catherine J. Wu, J. Ritz, 2012, Leukemia.

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.

J. Ritz, S. Nikiforow, P. Armand, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TRANSPLANTATION Ef ﬁ cacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

J. Ritz, S. Nikiforow, J. Whangbo, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?

P. Armand, P. Corradini, A. Guidetti, 2019, HemaSphere.

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

A. LaCasce, A. Freedman, P. Armand, 2013, British journal of haematology.

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020, Blood advances.

Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation.

P. Richardson, S. Nikiforow, P. Armand, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

A. LaCasce, A. Freedman, P. Armand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

A. LaCasce, A. Freedman, P. Armand, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

A. LaCasce, D. Neuberg, P. Armand, 2018, Blood.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

P. Richardson, K. Stevenson, P. Armand, 2008, Blood.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma.

A. Nademanee, D. Maloney, P. Armand, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Emily M. Thrash, S. Tyekucheva, S. Fernandes, 2021, Leukemia.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

M. Terol, C. Solano, P. Armand, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Gribben, J. Ritz, K. Stevenson, 2008 .

Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation

A. LaCasce, J. Ritz, M. Faham, 2015 .

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

A. LaCasce, S. Tyekucheva, P. Armand, 2020, Blood.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

A. LaCasce, S. Tyekucheva, P. Armand, 2019, Blood.

Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011 .

Cancer Therapy : Clinical Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011 .

Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.

D. Neuberg, P. Armand, M. Davids, 2015 .

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

J. Ritz, S. Nikiforow, P. Armand, 2018, Haematologica.

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

P. Armand, A. Herrera, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma

V. Carlton, J. Ritz, M. Faham, 2016, British journal of haematology.

Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma

A. LaCasce, D. Neuberg, Y. Oki, 2013, British journal of haematology.

transplantation Prostaglandin-modulated umbilical cord blood hematopoietic stem cell

L. Zon, W. Goessling, C. Desponts, 2014 .

The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

P. Armand, R. Soiffer, Yi-Bin Chen, 2016, British journal of haematology.

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.

J. Ritz, P. Armand, R. Soiffer, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

S. Nikiforow, P. Armand, R. Soiffer, 2015, Haematologica.

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

J. Ritz, P. Armand, D. DeAngelo, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

J. Ritz, S. Nikiforow, J. Whangbo, 2019, Blood advances.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Sonali M. Smith, P. Armand, S. Jaglowski, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation

A. Letai, J. Ritz, P. Armand, 2014, Haematologica.

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

J. Ritz, P. Armand, R. Soiffer, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.

P. Armand, R. Soiffer, C. Cutler, 2012 .

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Matthew J. Frigault, R. Houot, V. Torri, 2021, Leukemia.

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

Matthew J. Frigault, J. Ritz, D. Maloney, 2018, Blood.

Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study

J. Ritz, K. Stevenson, P. Armand, 2010 .

TRANSPLANTATION Validation and re fi nement of the Disease Risk Index for allogeneic stem cell transplantation

M. Horowitz, P. Armand, R. Soiffer, 2014 .

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes

H. Deeg, P. Armand, R. Soiffer, 2009, Bone Marrow Transplantation.

transplantation in adults depends on reconstitution of thymopoiesis Clearance of CMV viremia and survival after double umbilical cord blood

J. Ritz, K. Stevenson, P. Armand, 2013 .

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

W. Chan, D. Weisenburger, A. LaCasce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

P. Richardson, S. Nikiforow, P. Armand, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies

O. Levy, P. Armand, Simon Doss-Gollin, 2022, Open forum infectious diseases.

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.

Matthew J. Frigault, A. LaCasce, M. Shipp, 2020, Blood advances.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

A. LaCasce, D. Neuberg, A. Lane, 2012, Leukemia & lymphoma.

Does iron overload really matter in stem cell transplantation?

R. Kwong, E. Neufeld, P. Armand, 2011, American journal of hematology.

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

M. Sorror, R. Storb, F. Appelbaum, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

M. Shipp, N. Johnson, J. Radford, 2016 .

Hyperferritinemia in stem cell transplantation.

P. Armand, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, J. Plutzky, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.

P. Armand, S. Koo, F. Marty, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

J. Laubach, P. Richardson, P. Armand, 2014 .

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.

P. Armand, Jennifer L. Crombie, J. Crombie, 2020, Surgical oncology clinics of North America.

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.

P. Armand, Jennifer L. Crombie, J. Crombie, 2019, Hematology/oncology clinics of North America.

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

M. Millenson, M. Shipp, A. Ligon, 2014 .

Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy

R. Advani, P. Armand, J. Chavez, 2020, British journal of haematology.

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

M. Shipp, A. Lesokhin, P. Armand, 2016 .

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

V. Seshan, Sonali M. Smith, A. Zelenetz, 2020 .

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

W. Chan, D. Weisenburger, A. Nademanee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

M. Shipp, P. Zinzani, P. Armand, 2015 .

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)

M. Shipp, A. Lesokhin, P. Armand, 2015 .

Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.

Christine F. Wogan, A. LaCasce, O. Mawlawi, 2018, Blood advances.

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay

A. LaCasce, A. Freedman, P. Armand, 2020, Leukemia & lymphoma.

Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study.

N. Girard, S. Hervé, V. Bouvier, 2019, Surgery.

Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.

J. Laubach, P. Richardson, P. Armand, 2013 .

Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.

Troxel, R. Advani, P. Armand, 2020, The oncologist.

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

P. Hari, P. Armand, L. Andritsos, 2016 .

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

M. Shipp, N. Johnson, J. Radford, 2021, Blood.

The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, J. Blossom, 2012, Biology of Blood and Marrow Transplantation.

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

M. Shipp, P. Zinzani, P. Armand, 2016 .

Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma: A Rare Tumor and a Challenging Diagnosis

S. Rodig, E. Burks, E. Morgan, 2012 .

Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy

P. Armand, R. Soiffer, C. Cutler, 2010, Bone Marrow Transplantation.

Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

A. LaCasce, P. Armand, D. Fisher, 2008 .

Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.

P. Armand, Haesook T. Kim, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

undergoing myeloablative stem cell transplantation Prognostic impact of elevated pre-transplant serum ferritin in patients

P. Armand, C. Cutler, Haesook T. Kim, 2013 .

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY

M. Shipp, J. Radford, P. Zinzani, 2017 .

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

M. Shipp, N. Johnson, J. Radford, 2018, Blood.

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2010 .

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S

S. Sen, P. Armand, M. Duh, 2021, The oncologist.

Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma

A. LaCasce, M. Shipp, S. Mukundan, 2016 .

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

G. Salles, D. Neuberg, M. Shipp, 2018, Blood.

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

A. LaCasce, A. Freedman, P. Armand, 2020, Blood.

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

M. Shipp, N. Johnson, J. Radford, 2016 .

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

K. Savage, M. Shipp, A. Santoro, 2018, Blood.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

M. Millenson, A. Santoro, P. Zinzani, 2016 .

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

J. Connors, P. Armand, K. Johnston, 2019, Blood.

CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study

J. Ritz, S. Nikiforow, P. Armand, 2013 .

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

A. LaCasce, D. Neuberg, P. D. Dal Cin, 2015, Leukemia and Lymphoma.

Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation

D. Weisenburger, A. LaCasce, A. Nademanee, 2015 .

FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation

W. Goessling, C. Desponts, J. Ritz, 2011 .

HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

K. Savage, U. Jaeger, M. Shipp, 2021 .

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, P. Armand, S. Treon, 2015, Leukemia.

Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study

P. Zinzani, P. Armand, J. Palcza, 2019, Clinical Trials.

Reply to J. Mehta

A. LaCasce, A. Freedman, P. Armand, 2009 .

54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation

A. LaCasce, A. Freedman, P. Armand, 2008 .

Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).

P. Armand, R. Soiffer, Shuli Li, 2007 .

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

E. D. Jacobsen, A. LaCasce, M. Shipp, 2022, Blood advances.

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

I. Flinn, B. Keyt, P. Armand, 2020 .

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

G. Salles, M. Shipp, P. Zinzani, 2017 .

PD-1 modulates regulatory T cell homeostasis during low-dose IL-2 therapy

J. Ritz, M. Tanimoto, P. Armand, 2017 .

S821 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR EXTENDED FOLLOW-UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY

K. Savage, S. Ansell, P. Armand, 2019, HemaSphere.

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Catherine J. Wu, S. Nikiforow, P. Armand, 2018, Blood.

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation

A. LaCasce, M. Shipp, J. Ritz, 2018, Blood.

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma

R. Advani, P. Armand, Y. Nieto, 2019, Blood.

Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma

E. D. Jacobsen, P. Armand, D. Fisher, 2022, Bone Marrow Transplantation.

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

L. Zon, W. Goessling, C. Desponts, 2013, Blood.

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

A. Alencar, A. LaCasce, S. Tyekucheva, 2021, Blood.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, P. Armand, 2016, Journal of Clinical Oncology.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Sonali M. Smith, M. Perales, R. Gale, 2016, Blood.

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Catherine J. Wu, P. Armand, R. Soiffer, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

F. Hodi, P. Armand, M. Davids, 2016, The New England journal of medicine.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

A. LaCasce, D. Neuberg, B. Ebert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.

P. Armand, Haesook T. Kim, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

D. Neuberg, Catherine J. Wu, G. Dranoff, 2013, The Journal of clinical investigation.

Running Title: Haploidentical vs. Unrelated Donor Transplant

M. Horowitz, P. Armand, S. Devine, 2015 .

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

J. Ritz, P. Armand, R. Soiffer, 2013, Blood.

Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors

J. Ritz, M. Perales, P. Zinzani, 2015 .

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

J. Ritz, K. Stevenson, P. Armand, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

J. Ritz, K. Stevenson, P. Armand, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.

P. Armand, K. Ballen, R. Soiffer, 2007 .

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

J. Ritz, K. Stevenson, P. Armand, 2010, Blood.

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

M. Shipp, P. Zinzani, P. Armand, 2015 .

130: Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis

P. Armand, K. Ballen, R. Soiffer, 2008 .

Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk

A. LaCasce, D. Neuberg, P. Armand, 2010 .

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011, Clinical Cancer Research.

Genetic Predispositions, Management Strategies, and Clinical Outcomes in Adults with Hemophagocytic Lymphohistiocytosis (HLH) after Reduced-Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (HSCT) at Dana-Farber Cancer Institute

J. Ritz, S. Nikiforow, P. Armand, 2019, Biology of Blood and Marrow Transplantation.